Member Info for mazik

I hope so even if I make 100k I will be dancing on the street..topped up another 250k at 6.50...bargain basement

Twohits agreed, enormous potential with news all this month and July...

Good morning Truth Caller, Gold and Lithium...all the best folks and the Bod is there next week for the meeting with Mali Government..for the Licence...

Sadoldgit its been very volatile movement feel its found a base at 8p, well looking forward at Friday's closing..

It's the next Ncyt.....sit, relax for 15p for today when the US opens

Feel that double figures by lunch , no worries of placement or speeding ticket. Reminds me of Pyc a few years ago which moved up from 2p to 30p within a week. Here we are waiting for update on Agile or a bid....Sticking for 50p on news market of a billion...imo

No need of speeding ticket neither any placement in the coming months before the Agile news....north to 50p

The UKRI-funded Covid-19 research project for SDC-1801 continues on schedule with the experimental phases finishing by the end of June and the data analysis to complete shortly thereafter. The Company will provide a further update once the relevant data are available. Bring it on 50p by July

Needs to be rerated mcap below 17m is too low...10p at least

Great to be in, thanks to the impatient

Diabetes cure is enormous patent of AZD1656 and Professor Sir Christopher Evans at the helm and the cure being developed as a potential therapeutic for diabitic sufferers to be able to commercialise will have enormous potential.. bought in and where it will take us in months ahead.

Potential here around £500 mcap as a starter 15p imo

Mcap at least £500m before news IMO

Rentless buying, trend is our friend.

Great potential as we stand "SDC-1802, is focused on cancer and holds first-in-class promise with value to be unlocked with clinical validation. The out-licensed assets, SRA737 and FLT3+Aurora kinase, are currently de-prioritised but offer upside potential on revived activity.".

Once in a life time potential, it should command at least be multiples of todays valuation, SDC-1801's Phase Ia clinical study (easiest to recruit; potential c $40bn market, albeit a very crowded one), we expect Sareum to get better mileage from prospecting other, less explored, autoimmune conditions such as lupus ($1.9bn market but less crowded) and inflammatory bowel disease (IBD - $16bn market) where its dual action may offer greater therapeutic gains.

Sareum has been awarded a grant of approximately £174,000 by UK Research & Innovation (“UKRI”) to investigate the therapeutic potential of SDC-1801 in preclinical models of severe phase Covid-19.
Positive results in its Covid-19 studies might lead to further opportunities for the Company to investigate SDC-1801 in treating severe and life-threatening inflammation that occurs as a result of other viral infections.
Further details can be made available to potential funding, collaboration and/or licensing partners on request.

Bounce for next range 5p to 8p.. mcap 500m...gla

Sareum, will help us to further explore the potential benefit of SDC-1801 against Covid-19 and TYK2/JAK1 inhibitor SDC-1802 against cancers.

There could be 6p by close